Dong Z, Wang S, Liu Z, Han E, Wu C, Luo C
JTCVS Tech. 2024; 28:50-58.
PMID: 39669317
PMC: 11632347.
DOI: 10.1016/j.xjtc.2024.09.006.
Federspiel J, Pfeifer J, Ramsthaler F, Reil J, Schmidt P, Sequeira V
Diagnostics (Basel). 2024; 14(22).
PMID: 39594199
PMC: 11592529.
DOI: 10.3390/diagnostics14222534.
Newman N, Burke M
Int J Mol Sci. 2024; 25(21).
PMID: 39519012
PMC: 11546582.
DOI: 10.3390/ijms252111460.
Banthiya S, Check L, Atkins J
US Cardiol. 2024; 18:e17.
PMID: 39508003
PMC: 11539043.
DOI: 10.15420/usc.2023.21.
Gill R, Siddiqui A, Yee B, DiCaro M, Houshmand N, Tak T
J Cardiovasc Dev Dis. 2024; 11(9).
PMID: 39330348
PMC: 11431942.
DOI: 10.3390/jcdd11090290.
Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy - an updated Meta-Analysis of randomized controlled trials.
Ullah I, Tayyaba Rehan S, Khan Z, Shuja S, Shuja M, Irfan M
Int J Cardiol Heart Vasc. 2024; 53:101467.
PMID: 39108740
PMC: 11301103.
DOI: 10.1016/j.ijcha.2024.101467.
Acute Left Ventricular Ballooning: Tools to Differentiate Hypertrophic Cardiomyopathy with Outflow Obstruction from Neurohumoral Takotsubo Syndrome.
Singh A, Razzouk L, Massera D, Sherrid M
Rev Cardiovasc Med. 2024; 24(5):154.
PMID: 39076741
PMC: 11273027.
DOI: 10.31083/j.rcm2405154.
Mavacamten Short-Term Hemodynamic, Functional, and Electrocardiographic Outcomes: Initial Real-World Post-Trial Experience.
Abdelfattah O, Lander B, DeMarco K, Richards K, Dubose D, Martinez M
JACC Adv. 2024; 2(10):100710.
PMID: 38938484
PMC: 11198066.
DOI: 10.1016/j.jacadv.2023.100710.
Lifetime Clinical Course of Hypertrophic Cardiomyopathy: Outcome of the Historical Florence Cohort Over 5 Decades.
Maurizi N, Olivotto I, Maron M, Bonacchi G, Antiochos P, Tomberli B
JACC Adv. 2024; 2(4):100337.
PMID: 38938243
PMC: 11198069.
DOI: 10.1016/j.jacadv.2023.100337.
Natural history and clinical outcomes of patients with hypertrophic cardiomyopathy from thin filament mutations.
Saul T, Bui Q, Argiro A, Keyt L, Olivotto I, Adler E
ESC Heart Fail. 2024; 11(6):3501-3510.
PMID: 38773858
PMC: 11631233.
DOI: 10.1002/ehf2.14848.
A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy.
Sawan M, Prabakaran S, DSouza M, Behbahani-Nejad O, Gold M, Williams B
Clin Cardiol. 2024; 47(1):e24207.
PMID: 38269637
PMC: 10766000.
DOI: 10.1002/clc.24207.
Altering Calcium Sensitivity in Heart Failure: A Crossroads of Disease Etiology and Therapeutic Innovation.
Saad N, Mashali M, Repas S, Janssen P
Int J Mol Sci. 2023; 24(24).
PMID: 38139404
PMC: 10744146.
DOI: 10.3390/ijms242417577.
Randomized Controlled Trial of Moderate- and High-Intensity Exercise Training in Patients With Hypertrophic Cardiomyopathy: Effects on Fitness and Cardiovascular Response to Exercise.
MacNamara J, Dias K, Hearon Jr C, Ivey E, Delgado V, Saland S
J Am Heart Assoc. 2023; 12(20):e031399.
PMID: 37830338
PMC: 10757533.
DOI: 10.1161/JAHA.123.031399.
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
Braunwald E, Saberi S, Abraham T, Elliott P, Olivotto I
Eur Heart J. 2023; 44(44):4622-4633.
PMID: 37804245
PMC: 10659958.
DOI: 10.1093/eurheartj/ehad637.
Systolic third sound associated with systolic anterior motion of the mitral valve in cats with obstructive hypertrophic cardiomyopathy.
Saponaro V, Mey C, Vonfeld I, Chamagne A, Alvarado M, Cadore J
J Vet Intern Med. 2023; 37(5):1679-1684.
PMID: 37448142
PMC: 10472982.
DOI: 10.1111/jvim.16806.
Is Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease?.
Bonaventura J, Rowin E, Maron M, Maron B
J Am Heart Assoc. 2023; 12(12):e028974.
PMID: 37301765
PMC: 10356023.
DOI: 10.1161/JAHA.122.028974.
The medical treatment of cardiogenic shock.
Lescroart M, Pequignot B, Janah D, Levy B
J Intensive Med. 2023; 3(2):114-123.
PMID: 37188116
PMC: 10175741.
DOI: 10.1016/j.jointm.2022.12.001.
Mechanisms of Sarcomere Protein Mutation-Induced Cardiomyopathies.
Barefield D, Alvarez-Arce A, Araujo K
Curr Cardiol Rep. 2023; 25(6):473-484.
PMID: 37060436
PMC: 11141690.
DOI: 10.1007/s11886-023-01876-9.
Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions.
Girolami F, Gozzini A, Palinkas E, Ballerini A, Tomberli A, Baldini K
J Clin Med. 2023; 12(7).
PMID: 37048573
PMC: 10095452.
DOI: 10.3390/jcm12072489.
Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care.
Garmany R, Bos J, Ommen S, Ackerman M, Geske J
ESC Heart Fail. 2023; 10(3):1919-1927.
PMID: 36987533
PMC: 10192262.
DOI: 10.1002/ehf2.14345.
